CRISPR-Based Diagnostics Market to Reach US$ 12.09 Billion by 2033 Driven by Rapid Molecular Testing, Advancements in CRISPR Technologies, and Growing Demand for Point-of-Care Diagnostics

The CRISPR-Based Diagnostics Market reached US$ 3.04 billion in 2024 and is expected to reach US$ 12.09 billion by 2033, growing at a CAGR of 16.7% during the forecast period 2025-2033.

Growth is driven by the increasing demand for rapid, accurate, and cost-effective diagnostic solutions, particularly for infectious diseases, genetic disorders, and point-of-care testing. CRISPR-based technologies enable highly specific and sensitive detection of nucleic acids, offering advantages such as faster turnaround times, portability, and scalability. Additionally, rising investments in molecular diagnostics, biotechnology research, and precision medicine, along with advancements in CRISPR-Cas systems and assay development, are accelerating market expansion. The growing focus on early disease detection, pandemic preparedness, and decentralized diagnostics is further fueling the global growth of the CRISPR-based diagnostics market.

Download your exclusive sample report(corporate email gets priority access): https://www.datamintelligence.com/download-sample/crispr-based-diagnostics-market?praneetha

✦ CRISPR-Based Diagnostics Market: Competitive Intelligence
The major global players in the market include OraSure Technologies, Inc., Mammoth Biosciences, Inc., Integrated DNA Technologies (IDT), GenScript, among others.

The CRISPR-Based Diagnostics Market is driven by biotechnology companies and genomic solution providers such as Mammoth Biosciences, GenScript, and IDT, which are leveraging CRISPR gene-editing technology for rapid, accurate, and cost-effective diagnostic testing. These solutions enable precise detection of pathogens, genetic mutations, and infectious diseases, supporting applications in clinical diagnostics, point-of-care testing, and research.

These companies' complementary strengths including Mammoth Biosciences' CRISPR-based detection platforms, IDT's expertise in nucleic acid technologies, GenScript's gene synthesis capabilities, and OraSure's diagnostics commercialization experience are strengthening competitive positioning. Continuous investments in next-generation CRISPR assays, portable diagnostic devices, rapid testing kits, and regulatory approvals are driving market growth amid increasing demand for early disease detection, decentralized diagnostics, and advanced molecular testing technologies.

Ready to scale in the Sapphire Glass Market ? Connect with the right partners and unlock new growth opportunities :- https://www.datamintelligence.com/partner-identification-enquiry/crispr-based-diagnostics-market?praneetha

✦ New Product Launches
Sherlock Biosciences
Sherlock Biosciences expanded its CRISPR-based diagnostic platform with rapid molecular testing solutions designed for infectious diseases. The systems leverage CRISPR technology for highly specific and sensitive detection of genetic material. These innovations enable faster, point-of-care diagnostics with minimal equipment requirements.

Mammoth Biosciences
Mammoth Biosciences introduced next-generation CRISPR diagnostic tools focused on ultra-sensitive detection and multiplex testing capabilities. The products are designed for scalability and ease of use in clinical and field settings. These developments support broader adoption of CRISPR diagnostics across healthcare applications.

✦ R&D Developments
Intellia Therapeutics
Intellia continued R&D in CRISPR technologies, including diagnostic applications for detecting genetic mutations and disease markers. The company is focusing on improving precision, specificity, and delivery systems. These advancements aim to expand the clinical utility of CRISPR-based diagnostics.

Broad Institute
The Broad Institute advanced research in CRISPR-based detection platforms, including SHERLOCK and DETECTR systems. The developments focus on improving sensitivity, speed, and versatility of molecular diagnostics. These innovations are enabling rapid detection of pathogens and genetic conditions.

✦ Technological Advancements
Rapid & Point-of-Care Molecular Diagnostics
The market is witnessing strong advancements in CRISPR-based rapid diagnostic tools that deliver results within minutes. These technologies offer high accuracy without the need for complex laboratory infrastructure. This makes them ideal for decentralized and resource limited settings.

Multiplex & High Sensitivity Detection
Technological progress is enabling CRISPR diagnostics to detect multiple targets simultaneously with high sensitivity. These systems improve disease detection capabilities and support early diagnosis. This advancement is critical for infectious disease management and genetic screening.

✦ M&A / Strategic Developments
Thermo Fisher Scientific
Thermo Fisher continued strategic collaborations and investments in CRISPR technologies, including diagnostic applications. The company is focusing on integrating CRISPR tools into its molecular diagnostics portfolio. These initiatives support innovation and commercialization in genetic testing.

Danaher Corporation
Danaher pursued strategic expansions in life sciences and diagnostics, including CRISPR-related technologies through its subsidiaries. The company is focusing on enhancing its genomic and molecular testing capabilities. This strengthens its position in the advanced diagnostics market.

Request Custom Intelligence Report: https://www.datamintelligence.com/customize/crispr-based-diagnostics-market?praneetha

✦ Market Segmentation
By Technique
The market is segmented into CRISPR-Cas12 35%, CRISPR-Cas13 30%, CRISPR-Cas9 20%, and Others 15%, with CRISPR-Cas12 dominating due to its high sensitivity and effectiveness in DNA-based detection. Cas13 is widely used for RNA detection, especially in infectious disease diagnostics.

By Product
The market includes Reagents & Kits 50%, Instruments 30%, and Software & Services 20%, with reagents & kits dominating due to recurring demand in diagnostic testing and research applications.

By Application
Applications include Infectious Disease Diagnostics 40%, Oncology 25%, Genetic Disorder Testing 20%, and Others 15%, with infectious disease diagnostics dominating due to rapid detection capabilities and increasing demand for point-of-care testing.

By End-User
End-users include Hospitals & Clinics 35%, Diagnostic Laboratories 30%, Research Institutes 20%, and Others 15%, with hospitals & clinics dominating due to increasing adoption of advanced diagnostic technologies for rapid and accurate testing.

✦ Regional Analysis
North America - 40% Share
North America leads with 40% share driven by strong biotechnology ecosystem, advanced research infrastructure, and high investment in genomic technologies.

Europe - 25% Share
Europe accounts for 25% share supported by increasing research activities and adoption of advanced diagnostic tools.

Asia-Pacific - 22% Share
Asia-Pacific holds 22% share due to growing healthcare investments, expanding biotech sector, and rising demand for rapid diagnostics.

Purchase Corporate License | Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=crispr-based-diagnostics-market?praneetha

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.